fibroblast activation protein (mF3) universal CAR T-cells

Fibroblast activation protein (mF3) universal CAR T-cells are an allogeneic, 'off-the-shelf' adoptive cell therapy developed by Cellectis. These T-cells are engineered using TALEN-based gene editing to be non-alloreactive and immune-evasive by knocking out the TRAC and B2M genes, respectively. The cells express a chimeric antigen receptor (CAR) featuring the mF3 scFv, which targets Fibroblast Activation Protein (FAP) expressed on cancer-associated fibroblasts (CAFs). By depleting CAFs, these UCAR T-cells aim to remodel the desmoplastic and immunosuppressive tumor microenvironment of stroma-rich solid tumors, such as triple-negative breast cancer, thereby facilitating the infiltration and efficacy of subsequent treatments like tumor-antigen-targeted CAR T-cells or checkpoint inhibitors. The mF3 scFv is an anti-murine antibody fragment that cross-reacts with human FAP protein.

Other names

FAP-targeting universal CAR T-cellsanti-FAP UCAR T-cellsmF3 FAP-CAR T-cellsmF-3 FAP-CAR T-cellsmF 3 FAP-CAR T-cells